Pharmaceuticals News and Research

RSS

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

The Epilepsy Therapy Project (ETP) and the Epilepsy Foundation (EF) today announced the latest grant recipients of its New Therapy Grants Program, a unique joint venture of the non-profit epilepsy organizations, to advance promising epilepsy research in clinical development. The grant awards, totaling approximately $200,000 in funding, will support an experimental gene therapy that directly targets epileptogenic brain tissue, as well as an electrode system that has the potential to improve the efficacy of surgical therapies for certain epilepsy syndromes.

24 Aug 2010

Researchers find new drug to treat circadian rhythm disorders

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) and the Medical Research Council (MRC) have successfully used a drug to reset and restart the natural 24 hour body clock of mice in the lab. The ability to do this in a mammal opens up the possibility of dealing with a range of human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.

24 Aug 2010

WHO calls on countries to prevent, control spread of antibiotic resistant bacteria

Amid the growing threat of antimicrobial resistance, the WHO on Friday urged countries to take greater action to limit the spread of drug-resistant bacteria, CIDRAP News reports. "Calling such pathogens 'a growing and global public health problem,' the WHO said, 'Countries should be prepared to implement hospital infection control measures to limit the spread of multi-drug resistant strains and to reinforce national policy on prudent use of antibiotics, reducing the generation of antibiotic resistant bacteria,'" according to the news service (Roos, 8/20).

24 Aug 2010

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at The Parkinson's Institute and the Mayo Clinic have published new research findings in the journal Public Library of Science (PLoS). The new data show effective silencing of the alpha-synuclein gene with an RNAi therapeutic administered directly to the substantia nigra in the CNS of non-human primates.

24 Aug 2010

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

24 Aug 2010

Preclinical studies of BIND-014 to be presented at ACS National Meeting

BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year. BIND-014 is a targeted, polymeric nanoparticle containing the cytotoxic agent, docetaxel, which is approved in major cancer indications, including breast, prostate and lung.

23 Aug 2010

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

Novo Nordisk Inc. today announced that it has signed an exclusive agreement with Upsher-Smith Laboratories, Inc. to market Vagifem (estradiol vaginal tablets) 10 mcg. Under the terms of the agreement, Upsher-Smith will exclusively market Vagifem 10 mcg to physicians in the U.S. beginning August 2 through the company's existing field sales force.

23 Aug 2010

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory bromfenac with InSite Vision's proprietary DuraSite technology.

23 Aug 2010

China Yongxin Pharmaceuticals second-quarter 2010 revenue increases 21.8 % to $11.16 million

China Yongxin Pharmaceuticals Inc., a wholesale distributor and retailer of pharmaceuticals and health-related products in Jilin province in the northeastern region of China, today announced its financial results for the second quarter ending June 30, 2010.

23 Aug 2010

Taro Pharmaceutical first half 2010 net income increases to $29 million

Taro Pharmaceutical Industries Ltd. today provided preliminary, unaudited and unreviewed information on its financial performance for the first half of 2010.

23 Aug 2010

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Alexion Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has approved Alexion's Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of commercial supply for Soliris® (eculizumab).

23 Aug 2010

Martin Karplus receives 2010 Russell Varian Prize for NMR innovation

Agilent Technologies Inc. announced Martin Karplus, professor emeritus, Department of Chemistry and Chemical Biology, Harvard University; and Laboratoire de Chimie Biophysique, ISIS, Université Louis Pasteur, the winner of the 2010 Russell Varian Prize.

23 Aug 2010

Hospira Japan receives approval for long term use of Precedex IV sedative

Hospira Japan Co., Ltd. today announced it has received an approval for the long-term (greater than 24 hour) use of the sedative "Precedex IV™200ug" (generic name: dexmedetomidine hydrochloride). This approval follows Hospira's first launches earlier this year of Precedex in Canada and in South Korea, important milestones for Hospira as the company continues to build the molecule's global presence.

23 Aug 2010

US oncology announces its contributions in development of 42 novel cancer therapies

US Oncology, Inc., the nation's leading integrated oncology company, announced today that in less than two decades it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration.

21 Aug 2010

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Skeletal muscles combust both lipids and carbohydrates during exercise. The carbohydrates consist of both glycogen stored in the muscles as well as glucose extracted from the blood. Being a major sink for glucose disposal, skeletal muscle represents an important model tissue for studying the intracellular signaling pathways leading to increased glucose transport.

21 Aug 2010

Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia

Jazz Pharmaceuticals, Inc. announced that the Joint Advisory Committee of the U.S. Food and Drug Administration (FDA), including the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, voted 20-2 that the benefit/risk balance did not support the approval of JZP-6 for the treatment of with the currently proposed Risk Evaluation Mitigation Strategy (REMS).

21 Aug 2010

Kendall Law Group to investigate potential breaches of fiduciary duties by SciClone Pharmaceuticals

Kendall Law Group, a national securities firm led by a former federal judge Joe Kendall with attorneys that include a former U.S. Attorney, is investigating SciClone Pharmaceuticals, Inc. for shareholders.

21 Aug 2010

WHO calls upon countries to be alert to antimicrobial resistance

Antimicrobial resistance (AMR) - the ability of micro-organisms to find ways to evade the action of the drugs used to cure the infections they cause - is increasingly recognised as a global public health issue which could hamper the control of many infectious diseases. Some bacteria have developed mechanisms which render them resistant to many of the antibiotics normally used for their treatment (multi-drug resistant bacteria), so pose particular difficulties, as there may be few or no alternative options for therapy.

21 Aug 2010

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg.

21 Aug 2010

Cubist Pharmaceuticals ranked 31st on FORTUNE's 2010' 100 Fastest-Growing Companies' list

Cubist Pharmaceuticals, Inc. today announced it has been ranked 31st on FORTUNE's 2010 "100 Fastest-Growing Companies" list and the top pharmaceutical company. In the "Profit Growth" subgroup Cubist ranked 21st. The magazine will be on the newsstands on August 23 and the full list is available today online.

21 Aug 2010

Pharmaceuticals News and Research

Epilepsy Therapy Project, EF announce recipients of New Therapy Grants Program

Researchers find new drug to treat circadian rhythm disorders

WHO calls on countries to prevent, control spread of antibiotic resistant bacteria

Alpha-synuclein gene silencing effective for treating neurodegenerative disorders: Research

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Preclinical studies of BIND-014 to be presented at ACS National Meeting

Novo Nordisk reaches exclusive agreement to market Vagifem 10 mcg

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

China Yongxin Pharmaceuticals second-quarter 2010 revenue increases 21.8 % to $11.16 million

Taro Pharmaceutical first half 2010 net income increases to $29 million

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Martin Karplus receives 2010 Russell Varian Prize for NMR innovation

Hospira Japan receives approval for long term use of Precedex IV sedative

US oncology announces its contributions in development of 42 novel cancer therapies

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Jazz Pharmaceuticals disappointed with FDA Advisory Committee recommendation for JZP-6 in fibromyalgia

Kendall Law Group to investigate potential breaches of fiduciary duties by SciClone Pharmaceuticals

WHO calls upon countries to be alert to antimicrobial resistance

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Cubist Pharmaceuticals ranked 31st on FORTUNE's 2010' 100 Fastest-Growing Companies' list

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence